ZymoGenetics' Doug Williams discusses his next big step in biotech; No advisory meeting for Endo;

 @FierceBiotech: Dear Henri: Sanofi chief advises Genzyme against defensive moves. Report | Follow @FierceBiotech

 @JohnCFierce: Skin into blood, without the stem cell step? Story | Follow @JohnCFierce

> Departing ZymoGenetics CEO Doug Williams tells Xconomy: "I sort of feel that after 20-plus years in the business, I'm starting to figure out some of the do's and don'ts. I'm definitely not ready to stop. I enjoy working in this business. It's a real gift to be able to work around a bunch of smart people and do things that are ultimately good, in the sense we develop important drugs." Q&A

> The FDA says it no longer needs a meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review Endo's New Drug Application for the new oral formulation of long-acting oxymorphone. Endo release

> Merck has pulled its European app for a combo asthma therapy, citing regulatory issues. Story

> Snowdon has been awarded a new three-year contract worth up to $8.2 million in development support from the Defense Department for the discovery and preclinical development of novel medical treatments to combat biowarfare pathogens. Snowdon release

And Finally... According to a new study, a minute change in a particular gene is associated with a significantly higher willingness to donate. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.